Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Background Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition,...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Prostate Ročník 78; číslo 12; s. 889 - 895
Hlavní autoři:	Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary‐Ellen, Sweeney, Cristopher J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 01.09.2018
Témata:	ADT Aged Androgen Antagonists - administration & dosage Androgen Antagonists - therapeutic use Antineoplastic Agents Castration Classification Docetaxel - therapeutic use Humans Male Medical prognosis Metastases Metastasis mHSPC Middle Aged Neoplasm Metastasis - pathology Pain Prognosis prognostic classification Proportional Hazards Models Prostate cancer Prostate-Specific Antigen - analysis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Prostatic Neoplasms, Castration-Resistant Registries Retrospective Studies Survival Rate Time Factors time of metastatic disease volume of disease volume of disease ADT prognostic classification mHSPC time of metastatic disease
ISSN:	0270-4137, 1097-0045, 1097-0045
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!